Top

Published in:

01-06-2012 | Skeletal Biology (D Burr, Section Editor)

Pathways for Bone Loss in Inflammatory Disease

Authors: Tobias Braun, Georg Schett

Published in: Current Osteoporosis Reports | Issue 2/2012

Abstract

Chronic inflammation including autoimmune disease is an important risk factor for the development of osteoporosis. Receptor activator of nuclear factor-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) play a central role in osteoclast differentiation and function, and the molecular pathways by which M-CSF and RANKL induce osteoclast differentiation have been analyzed in detail. Proinflammatory cytokines directly or indirectly regulate osteoclastogenesis and bone resorption providing a link between inflammation and osteoporosis. Tumor necrosis factor-α, interleukin (IL)-1, IL-6, and IL-17 are the most important proinflammatory cytokines triggering inflammatory bone loss. Inhibition of these cytokines has provided potent therapeutic effects in the treatment of diseases such as rheumatoid arthritis. Further investigation is needed to understand the pathophysiology and to develop new strategies to treat inflammatory bone loss. This review summarizes new data on inflammatory bone loss obtained in 2011.

Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):235.PubMedCrossRef

• Nakashima T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–4. Osteocytes are a major source of RANKL and thus regulate bone homeostasis in vitro and in vivo..PubMedCrossRef

Yeo L, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis. 2011;70(11):2022–8.PubMedCrossRef

Ellabban AS, et al. Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int 2011, Feb 17.

Boumans MJ, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012;71(1):108–13.PubMedCrossRef

Mabilleau G, et al. Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT. Cytokine. 2012;57(2):294–9.PubMedCrossRef

• Jang E, et al. Deficiency of foxp3 regulatory T cells exacerbates autoimmune arthritis by altering the synovial proportions of CD4 T cells and dendritic cells. Immune Netw. 2011;11(5):299–306. Regulatory T cells protect from inflammatory bone loss in vivo reducing the influx of RANKL-positive cells into synovia..PubMedCrossRef

Claro T, et al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. PLoS One. 2011;6(4):e18748.PubMedCrossRef

• Lee SJ, et al. Bone destruction by receptor activator of nuclear factor kappaB ligand-expressing T cells in chronic gouty arthritis. Arthritis Res Ther. 2011;13(5):R164. This publication shows that RANKL contributes to the pathogenesis of human gouty arthritis..PubMedCrossRef

10.

Choe JY, Lee GH, Kim SK. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. J Rheumatol. 2011;38(3):485–91.PubMedCrossRef

11.

Hwang SY, Putney JW. Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J. 2011.

12.

Noh AL, et al. L-type Ca(2+) channel agonist inhibits RANKL-induced osteoclast formation via NFATc1 down-regulation. Life Sci. 2011;89(5–6):159–64.PubMedCrossRef

13.

Yamaguchi M, Weitzmann MN, Murata T. Exogenous regucalcin stimulates osteoclastogenesis and suppresses osteoblastogenesis through NF-kappaB activation. Mol Cell Biochem. 2012;359(1–2):193–203.PubMedCrossRef

14.

Lee YR, et al. SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis. Br J Pharmacol. 2011;164(2b):794–806.PubMed

15.

Soysa NS, et al. Defective nuclear factor-kappaB-inducing kinase in aly/aly mice prevents bone resorption induced by local injection of lipopolysaccharide. J Periodontal Res. 2011;46(2):280–4.PubMedCrossRef

16.

Liu S, et al. The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis. PLoS One. 2011;6(3):e17161.PubMedCrossRef

17.

Mabilleau G, Chappard D, Sabokbar A. Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem. 2011;286(5):3242–9.PubMedCrossRef

18.

Bishop KA, et al. Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem. 2011;286(23):20880–91.PubMedCrossRef

19.

Danks L, et al. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J Bone Miner Res. 2011;26(1):182–92.PubMedCrossRef

20.

Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13(4):R115.PubMedCrossRef

21.

Yoon SH, et al. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway. J Bone Miner Res. 2011;26(6):1217–29.PubMedCrossRef

22.

Bao X, et al. Acid sphingomyelinase regulates osteoclastogenesis by modulating sphingosine kinases downstream of RANKL signaling. Biochem Biophys Res Commun. 2011;405(4):533–7.PubMedCrossRef

23.

He Y, et al. Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One. 2011;6(9):e24780.PubMedCrossRef

24.

Kukita A, et al. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Arthritis Rheum. 2011;63(9):2744–54.PubMedCrossRef

25.

Mahoney DJ, et al. TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. Arthritis Rheum. 2011;63(4):1034–43.PubMedCrossRef

26.

Yasui T, et al. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J Bone Miner Res. 2011;26(11):2665–71.PubMedCrossRef

27.

Cantley MD, et al. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol. 2011;226(12):3233–41.PubMedCrossRef

28.

Kim JH, et al. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation. Biochem J. 2011;436(2):253–62.PubMedCrossRef

29.

Hodge JM, et al. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One. 2011;6(6):e21462.PubMedCrossRef

30.

Kimura K, et al. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo. FEMS Immunol Med Microbiol. 2012;64(2):219–27.PubMedCrossRef

31.

Chen Z, et al. The critical role of IL-34 in osteoclastogenesis. PLoS One. 2011;6(4):e18689.PubMedCrossRef

32.

Chemel M, et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(1):150–4.PubMedCrossRef

33.

Lee B, et al. Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. J Immunol. 2010;185(10):5926–34.PubMedCrossRef

34.

Ignatius A, et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1beta. J Cell Biochem. 2011;112(9):2594–605.PubMedCrossRef

35.

Lee GT, et al. Bone morphogenetic protein 6-induced interleukin-1beta expression in macrophages requires PU.1/Smad1 interaction. Mol Immunol. 2011;48(12–13):1540–7.PubMedCrossRef

36.

Schulze J, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res. 2011;26(4):704–17.PubMedCrossRef

37.

Saleh H, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 2011;152(5):1911–22.PubMedCrossRef

38.

• Keller J, et al. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun. 2012;417(1):217–22. Inhibition of osteoclastogenesis is an important function of IL-33 in vivo in mice..PubMedCrossRef

39.

• Zaiss MM, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol. 2011;186(11):6097–105. IL-33 reduces TNF-α–mediated inflammatory bone loss and osteoclast number in vivo in mice..PubMedCrossRef

40.

Funakoshi-Tago M, et al. JAK2 is an important signal transducer in IL-33-induced NF-kappaB activation. Cell Signal. 2011;23(2):363–70.PubMedCrossRef

41.

Ali S, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol. 2011;187(4):1609–16.PubMedCrossRef

42.

Saidi S, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine. 2011;53(3):347–54.PubMedCrossRef

43.

Kageyama Y, et al. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol. 2012;22(1):89–93.PubMedCrossRef

44.

Hong YS, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26(9):1132–9.PubMedCrossRef

45.

Talabot-Ayer D, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012;79(1):32–7.PubMedCrossRef

46.

Nagano K, et al. The tumor necrosis factor type 2 receptor plays a protective role in tumor necrosis factor-alpha-induced bone resorption lacunae on mouse calvariae. J Bone Miner Metab. 2011;29(6):671–81.PubMedCrossRef

47.

Atanga E, et al. TNFalpha inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone. 2011;49(5):1090–100.PubMedCrossRef

48.

Goto H, et al. Primary human bone marrow adipocytes support TNF-alpha-induced osteoclast differentiation and function through RANKL expression. Cytokine. 2011;56(3):662–8.PubMedCrossRef

49.

Yarilina A, et al. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc Natl Acad Sci USA. 2011;108(4):1573–8.PubMedCrossRef

50.

Finzel S, et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis. 2011;70(9):1587–93.PubMedCrossRef

51.

Huang H, et al. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif. 2011;44(5):420–7.PubMedCrossRef

52.

Tsukasaki M, et al. Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-alpha. Biochem Biophys Res Commun. 2011;410(4):766–70.PubMedCrossRef

53.

Suzuki M, et al. Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor kappaB ligand. Clin Exp Immunol. 2011;163(1):88–95.PubMedCrossRef

54.

Cheung WY, Simmons CA, You L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone. 2012;50(1):104–10.PubMedCrossRef

55.

Honda K. Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. J Oral Sci. 2011;53(1):87–96.PubMedCrossRef

56.

Terpos E, et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29(6):921–5.PubMed

57.

Kanbe K, et al. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int. 2011;Jul 26.

58.

Natsume H, et al. Wnt3a regulates tumor necrosis factor-alpha-stimulated interleukin-6 release in osteoblasts. Mol Cell Endocrinol. 2011;331(1):66–72.PubMedCrossRef

59.

Kato K, et al. AMP-activated protein kinase regulates PDGF-BB-stimulated interleukin-6 synthesis in osteoblasts: Involvement of mitogen-activated protein kinases. Life Sci. 2012;90(1–2):71–6.PubMedCrossRef

60.

Guo L, et al. Angiotensin II induces interleukin-6 synthesis in osteoblasts through ERK1/2 pathway via AT1 receptor. Arch Oral Biol. 2011;56(3):205–11.PubMedCrossRef

61.

Rego D, et al. IL-6 production is positively regulated by two distinct Src homology domain 2-containing tyrosine phosphatase-1 (SHP-1)-dependent CCAAT/enhancer-binding protein beta and NF-kappaB pathways and an SHP-1-independent NF-kappaB pathway in lipopolysaccharide-stimulated bone marrow-derived macrophages. J Immunol. 2011;186(9):5443–56.PubMedCrossRef

62.

Kamiya S, et al. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett. 2011;138(1):47–53.PubMedCrossRef

63.

Halvorsen EH, et al. Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand J Immunol. 2011;73(3):243–9.PubMedCrossRef

64.

Hueber AJ, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336–40.PubMedCrossRef

65.

• Pollinger B, et al. Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol. 2011;186(4):2602–12. This study shows in vivo that IL-17 produced by Th17 cells promotes inflammatory bone loss while IL-17 secreted by γδ T cells is less important..PubMedCrossRef

66.

Abdollahi-Roodsaz S, et al. Destructive role of myeloid differentiation factor 88 and protective role of TIR-containing adaptor inducing interferon beta in IL-17-dependent arthritis. Arthritis Rheum. 2011, Dec 6.

67.

Oostlander AE, et al. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn’s disease-associated bone loss. J Cell Biochem. 2012;113(1):260–8.PubMedCrossRef

68.

Park YE, et al. IL-17 increases cadherin-11 expression in a model of autoimmune experimental arthritis and in rheumatoid arthritis. Immunol Lett. 2011;140(1–2):97–103.PubMedCrossRef

69.

Zhang F, et al. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie. 2011;93(2):296–305.PubMedCrossRef

70.

Zwerina K, et al. Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol. 2012;42(2):413–23.PubMedCrossRef

71.

Sadik CD, et al. IL-17RA signaling amplifies antibody-induced arthritis. PLoS One. 2011;6(10):e26342.PubMedCrossRef

72.

Pickens SR, et al. Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis. 2011;14(4):443–55.PubMedCrossRef

73.

Rampersad RR, et al. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One. 2011;6(10):e25833.PubMedCrossRef

74.

Kaiwen W, et al. Changes and significance of IL-25 in chicken collagen II-induced experimental arthritis (CIA). Rheumatol Int. 2011;May 29.

75.

Yu M, et al. NF-kappaB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-kappaB pathways. J Immunol. 2011;187(4):1797–806.PubMedCrossRef

76.

Cheng J, et al. Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis. J Cell Biochem. 2011;112(11):3385–92.PubMedCrossRef

77.

Ma HM, Wu Z, Nakanishi H. Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. Lab Invest. 2011;91(6):921–31.PubMedCrossRef

78.

Kohara H, et al. IFN-gamma directly inhibits TNF-alpha-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett. 2011;137(1–2):53–61.PubMedCrossRef

79.

Ayon Haro ER, et al. Locally administered interferon-gamma accelerates lipopolysaccharide-induced osteoclastogenesis independent of immunohistological RANKL upregulation. J Periodontal Res. 2011;46(3):361–73.PubMedCrossRef

80.

Cheng J, et al. Molecular mechanisms of the biphasic effects of interferon-gamma on osteoclastogenesis. J Interferon Cytokine Res. 2012;32(1):34–45.PubMedCrossRef

81.

Yasui T, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res. 2011;26(7):1447–56.PubMedCrossRef

82.

Park MK, et al. IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis. Immunol Lett. 2011;139(1–2):42–51.PubMedCrossRef

83.

Kim YG, et al. The influence of interleukin-32gamma on osteoclastogenesis with a focus on fusion-related genes. J Clin Immunol. 2012;32(1):201–6.PubMedCrossRef

84.

Pickens SR, et al. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum. 2011;63(8):2289–98.PubMedCrossRef

85.

Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford). 2012;51(3):434–42.CrossRef

86.

Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010;62(11):3311–21.PubMedCrossRef

87.

Hsu YH, et al. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med. 2011;208(9):1849–61.PubMedCrossRef

88.

Kwok SK, et al. Interleukin-21 promotes osteoclastogenesis in rheumatoid arthritis in humans and mice. Arthritis Rheum. 2012;64(3):p740–51.CrossRef

89.

Marijnissen RJ, et al. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum. 2011;63(10):2939–48.PubMedCrossRef

90.

Kim KW, et al. IL-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2011;Oct 27.

91.

Guma M, et al. JNK1 controls mast cell degranulation and IL-1{beta} production in inflammatory arthritis. Proc Natl Acad Sci USA. 2010;107(51):22122–7.PubMedCrossRef

92.

Polzer K, et al. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum. 2011;63(3):670–80.PubMedCrossRef

93.

Zwerina K, et al. Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis. 2011;70(6):1122–9.PubMedCrossRef

94.

Bluml S, et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011;63(5):1281–8.PubMedCrossRef

95.

Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis. Blood. 2011;117(13):3648–57.PubMedCrossRef

96.

Nakasa T, et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 2011;63(6):1582–90.PubMedCrossRef

Title: Pathways for Bone Loss in Inflammatory Disease
Authors: Tobias Braun
Georg Schett
Publication date: 01-06-2012
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 2/2012
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-012-0104-5

At a glance: The STEP trials

Springer Medicine

Pathways for Bone Loss in Inflammatory Disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Role of Insulin-like Growth Factor-1 in the Regulation of Skeletal Growth

The Contribution of the Extracellular Matrix to the Fracture Resistance of Bone

The NPY System and its Neural and Neuroendocrine Regulation of Bone

Trabecular Architecture and Vertebral Fragility in Osteoporosis

Effects of Bone Matrix Proteins on Fracture and Fragility in Osteoporosis

The Interaction of Biological Factors with Mechanical Signals in Bone Adaptation: Recent Developments